Adipokine und Lipidstoffwechsel bei Typ-2-Diabetes

Schlüsselwörter

Adipokine - Lipide - Diabetes mellitus Typ 2 - metabolisches Syndrom

Key words

Adipokines - lipids - diabetes mellitus type 2 - metabolic syndrome

Literatur

• 1 Adiels M, Olofsson S O. et al . Diabetic dyslipidaemia.  Curr Opin Lipidol. 2006;  17 238-246
• 2 Baar R A, Dingfelder C S. et al . Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice.  Am J Physiol Endocrinol Metab. 2005;  288 E187-E193
• 3 Colhoun H M, Betteridge D J. et al . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.  Lancet. 2004;  364 685-696
• 4 Dobbins R L, Szczepaniak L S. et al . Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion.  Am J Physiol Endocrinol Metab. 2003;  284 E778-E787
• 5 Erikstrup C O, Mortensen H. et al . Retinol-binding protein 4 and insulin resistance.  N Engl J Med. 2006;  355 1393-1394
• 6 Evans J M, Wang J, Morris A D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.  Brit Med J. 2002;  324 939-942
• 7 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) . Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).  J Am Med Assoc. 2001;  285 2486-2497
• 8 Friedman J M. The function of leptin in nutrition, weight, and physiology.  Nutr Rev. 2002;  60 S1-14
• 9 Graham T E, Yang Q. et al . Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.  N Engl J Med. 2006;  354 2552-2563
• 10 Grundy S M, Cleeman J I. et al . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.  Circulation. 2004;  110 227-239
• 11 Haffner S M, Lehto S. et al . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
• 12 Havel P J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism.  Diabetes. 2004;  53 S143-151
• 13 Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors.  Endocr Rev. 2005;  26 439-451
• 14 McTernan P G, Kusminski C M. et al . Resistin.  Curr Opin Lipidol. 2006;  17 170-175
• 15 MRC/BHF . Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2004;  360 7-22
• 16 Oral E A, Simha V. et al . Leptin-replacement therapy for lipodystrophy.  N Engl J Med. 2002;  346 570-578
• 17 Rothenbacher D, Brenner H. et al . Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers.  Eur Heart J. 2005;  26 1640-1646
• 18 Sato N, Kobayashi K. et al . Adenovirus-mediated high expression of resistin causes dyslipidemia in mice.  Endocrinology. 2005;  146 273-279
• 19 Schneider J G, von Eynatten M. et al . Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo.  Diabetes Care. 2005;  28 2181-2186
• 20 Shetty G K, Economides P A. et al . Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.  Diabetes Care. 2004;  27 2450-2457
• 21 Smith J, Al-Amri M. et al . Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1.  Clin Endocrinol. 2006;  65 667-672
• 22 Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?.  Eur J Clin Invest. 2006;  36 621-625
• 23 Stephens J M, Vidal-Puig A J. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity.  Curr Opin Lipidol. 2006;  17 128-131
• 24 Takashima N, Tomoike H. et al . Retinol-binding protein 4 and insulin resistance.  N Engl J Med. 2006;  355 1392
• 25 von Eynatten M, Hamann A. et al . Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease.  Clin Chem. 2006;  52 853-859
• 26 von Eynatten M, Schneider J G. et al . Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance.  Diabetes Care. 2004;  27 2925-2929
• 27 von Eynatten M, Schneider J G. The role of adiponectin in atherosclerosis: do lipids tipp the scales?.  Future Cardiol. 2005;  1 775-784
• 28 Yamauchi T, Kamon J. et al . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.  Nat Med. 2002;  8 1288-1295
• 29 Yu Y H, Ginsberg H N. Adipocyte signaling and lipid homeostasis: sequelae of insulin resistant adipose tissue.  Circ Res. 2005;  96 1042-1052